This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spre…

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Small Cell Neuroendocrine Carcinoma+1 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05691465

Phase 1

A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine th…

Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma

~Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT06062745